Search research articles
Contact Us
Filters
Showing results (81-90 of 109) with videos related to
Page
of 11
Sort By:
The Lancet. Haematology
|
March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Blood
|
April 29, 2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV
Susanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, et al.
Haematologica
|
August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia
Sebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Cancer Journal
|
May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
Julia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Leukemia
|
December 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, et al.
Blood Cancer Journal
|
January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Jan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood Advances
|
August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Sebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Cancers
|
April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
Jan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Annals of Hematology
|
September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
Alice Fabarius, Lida Kalmanti, Christian T Dietz, et al.
Haematologica
|
April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
David Baden, Sven Zukunft, Gema Hernandez, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 109) with videos related to
Sort By:
Page
of 11
The Lancet. Haematology
|
March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Blood
|
April 29, 2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV
Susanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, et al.
Haematologica
|
August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia
Sebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Cancer Journal
|
May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
Julia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Leukemia
|
December 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, et al.
Blood Cancer Journal
|
January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Jan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood Advances
|
August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Sebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Cancers
|
April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
Jan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Annals of Hematology
|
September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
Alice Fabarius, Lida Kalmanti, Christian T Dietz, et al.
Haematologica
|
April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
David Baden, Sven Zukunft, Gema Hernandez, et al.
Page
of 11